Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Benitec Biopharma (BNTC) over the last 6 years, with Jun 2024 value amounting to $52.2 million.

  • Benitec Biopharma's Liabilities and Shareholders Equity rose 601.44% to $105.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $305.3 million, marking a year-over-year increase of 349.78%. This contributed to the annual value of $52.2 million for FY2024, which is 1069.58% up from last year.
  • Per Benitec Biopharma's latest filing, its Liabilities and Shareholders Equity stood at $52.2 million for FY2024, which was up 1,069.58% from $4.5 million recorded in FY2023.
  • In the past 5 years, Benitec Biopharma's Liabilities and Shareholders Equity registered a high of $52.2 million during FY2024, and its lowest value of $4.5 million during FY2023.
  • Over the past 3 years, Benitec Biopharma's median Liabilities and Shareholders Equity value was $6.0 million (recorded in 2022), while the average stood at $20.9 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 72.06% in 2022, then soared by 1,069.58% in 2024.
  • Yearly analysis of 5 years shows Benitec Biopharma's Liabilities and Shareholders Equity stood at $11.6 million in 2020, then spiked by 84.51% to $21.4 million in 2021, then slumped by 72.06% to $6.0 million in 2022, then declined by 25.26% to $4.5 million in 2023, then spiked by 1,069.58% to $52.2 million in 2024.